CAS: 157688-46-5; 2-(1-(Tert-Butoxycarbonyl)Piperidin-4-yl)Acetic Acid

相似化合物

73415-84-6 51052-78-9 63845-28-3

上下游产品

CAS号135716-09-5 1-B°C-4-哌啶乙酸乙酯 | CAS号24424-99-5 二碳酸二叔丁酯 | CAS号51052-78-9 4-哌啶乙酸 | CAS号73415-84-6 吡啶-4-乙酸盐酸盐 | CAS号6622-91-9 4-吡啶乙酸盐酸盐 | CAS号144-55-8 碳酸氢钠 | CAS号28356-58-3 4-吡啶乙酸 | CAS号59184-90-6 4-哌啶乙酸甲酯 | CAS号175213-46-4 N-B°C-4-哌啶乙酸甲酯 | CAS号34619-03-9 碳酸二叔丁酯 | CAS号142355-80-4 1-B°C-4-(4-甲氧基-... | CAS号916791-39-4 3-氧代-4-(1-b°C-4... | CAS号89151-44-0 N-B°C-4-哌啶乙醇 | CAS号142355-81-5 1-B°C-4-(4-溴丁基)-哌啶 | CAS号142374-19-4 4-(2-氧代乙基)哌啶-1-羧酸叔丁酯 | CAS号135716-09-5 1-B°C-4-哌啶乙酸乙酯 | CAS号142355-83-7 4-(1-B°C-4-哌啶基)-1-丁醇 | CAS号145508-94-7 1-叔丁氧羰基-4-碘甲基哌啶 | CAS号142247-38-9 N-B°C-4-哌啶丁酸 | CAS号193275-84-2 氯那法尼

4-吡啶乙酸盐酸盐置于platinum(Iv) Oxide Sodium Hydroxide,氢气体系中,用 1,4-二氧六环,溶剂黄146 用作溶剂,化学反应生成1-叔丁氧羰基-4-哌啶乙酸
参考文献:使用noyori催化剂不对称氢化3-亚烷基-2-哌啶酮.N-取代基对对映选择性的影响
标题:使用noyori催化剂不对称氢化3-亚烷基-2-哌啶酮.N-取代基对对映选择性的影响
摘要:发现由binap-Ru(II)配合物催化的3-亚烷基-2-哌啶酮不对称氢化中的对映选择性受内酰胺氮上的内部取代基的影响很大,在52中得到相应的3-烷基-2-哌啶酮-92%ee.
Doi:10.1016/0040-4039(95)01546-9

专利信息

专利号:US-2023295613-A1
优先权日:2020-02-14
标 题:Long chain carbon and cyclic amino acids substrates for genetic code reprogramming
发明人：JEWETT MICHAEL C; LEE JOONGOO; MOORE JEFFREY S; SCHWARZ KEVIN J
权利人:UNIV NORTHWESTERN; UNIV ILLINOIS
摘要:Abstract: Disclosed are methods, systems, components, and compositions for synthesis of sequence defined polymers. The methods, systems, components, and compositions may be utilized for incorporating novel substrates that include non-standard amino acid monomers and non-amino acid monomers into sequence defined polymers. As disclosed herein, the novel substrates may be utilized for acylation of tRNA via flexizyme catalyzed reactions. The tRNAs thus acylated with the novel substrates may be utilized in synthesis platforms for incorporating the novel substrates into a sequence defined polymer.

专利号:US-11814621-B2
优先权日:2018-06-01
标题 :Expanding the chemical substrates for genetic code reprogramming
发明人：JEWETT MICHAEL CHRISTOPHER; LEE JOONGOO; MOORE JEFFREY S; SCHWIETER KENNETH E; SCHWARZ KEVIN JEROME
权利人:UNIV NORTHWESTERN; UNIV ILLINOIS
摘要:Disclosed are methods, systems, components, and compositions for synthesis of sequence defined polymers. The methods, systems, components, and compositions may be utilized for incorporating novel substrates that include non-standard amino acid monomers and non-amino acid monomers into sequence defined polymers. As disclosed herein, the novel substrates may be utilized for acylation of tRNA via flexizyme catalyzed reactions. The tRNAs thus acylated with the novel substrates may be utilized in synthesis platforms for incorporating the novel substrates into a sequence defined polymer.

专利号:US-2024390383-A1
优先权日:2021-09-28
标题 :Dioxazines and their use in treatment of gba-related diseases
发明人：NEVE SØREN; BROWN WILLIAM DALBY; THIRSTRUP KENNETH
权利人:ZEVRA DENMARK AS
摘要:The present invention relates to dioxazines, their synthesis, and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.

专利号:WO-0102375-A1
优先权日:1999-07-01
标 题:Process for synthesizing oxadiazoles
发明人：DENER JEFFREY MARK; LY CUONG QUOC
权利人:AXYS PHARM INC; DENER JEFFREY MARK; LY CUONG QUOC
摘要:The present invention relates to a process for the synthesis of a single as well as large array of oxadiazole based organic compounds. These oxadiazole based organic compounds are represented by compounds of formula (I).

专利号:KR-20220005065-A
优先权日:2019-05-09
标题 :Synthesis of labeled imidazo[1,2-A]pyrimidine

专利号:US-9522901-B2
优先权日:2005-05-26
标题:Compositions and methods including cell death inducers and procaspase activation
发明人：HERGENROTHER PAUL J; PUTT KARSON S; PETERSON QUINN P; FAKO VALERIE
权利人:UNIV ILLINOIS
摘要:Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.